3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Breast Neoplasms
6
Neuroendocrine Tumors
5
Neoplasm Metastasis
3
Carcinoma, Renal Cell
3
Tuberous Sclerosis
2
Triple Negative Breast Neoplasms
2
Recurrence
2
Glioma
2
Endometrial Neoplasms
2
Adenoma, Islet Cell
2
von Hippel-Lindau Disease
1
Vascular Malformations
1
Unilateral Breast Neoplasms
1
Thymus Neoplasms
1
Seizures
1
Sarcoma, Kaposi
1
Sarcoma
1
Nevus
1
Myelodysplastic Syndromes
1
Multiple Endocrine Neoplasia Type 1
1
Metastatic Digestive System Neuroendocrine Tumor G1
1
Meningioma
1
Lymphangioma
1
Liposarcoma
1
Leukemia, Myeloid, Acute
1
Leiomyosarcoma
1
Kidney Neoplasms
1
Hemangioma
1
Hemangioendothelioma
1
Hamartoma Syndrome, Multiple
1
Interventions
olaparib
1
lutetium Lu 177 dotatate
1
lanreotide
1
fluorodopa F 18
1
cabozantinib
1
Sunitinib
1
Random Allocation
1
Octreotide
1
Nivolumab
1
Everolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoid Tumor
×
Everolimus
×
90 days
×
Clear all
NCT05477576
2026-03-30
ACTION-1
RayzeBio, Inc.
Phase 3
Recruiting
338 enrolled